한글목차

소라페닙(Sorafenib) 시장 규모는 최근 꾸준히 성장하고 있습니다. 2025년 12억 9,000만 달러에서 2026년에는 13억 4,000만 달러에 이르고, CAGR 3.8%의 성장이 전망되고 있습니다. 지금까지의 성장은 표적형 키나아제 억제제의 임상적 성공, 전 세계 암 부담 증가, 여러 적응증에 대한 소라페닙의 승인, 강력한 종양학 R&D 파이프라인, 특허에 기반한 시장 확대에 기인하는 것으로 보입니다.

소라페닙(Sorafenib) 시장 규모는 향후 몇 년간 꾸준한 성장이 전망됩니다. 2030년에는 15억 6,000만 달러에 이르고, CAGR은 3.9%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 제네릭 암 치료제 증가, 암 진단율 상승, 비용 효율적인 암 치료에 대한 집중, 암 의료 인프라 확충, 병용요법 연구 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 표적항암제 사용 확대, 제네릭 솔라페닙 제품 확대, 간암 및 신장암 치료에서의 채택 증가, 종양학에서의 병용요법 접근법, 신흥 시장에서의 종양학 약품 접근성 개선 등이 있습니다.

암 발생률 증가는 향후 몇 년 동안 소라페닙 시장의 성장을 견인할 것으로 예측됩니다. 암은 통제할 수 없는 세포 증식을 특징으로 하며, 주변 조직으로의 침윤과 다른 부위로의 전이 가능성을 동반하는 질환군입니다. 암 유병률 증가는 고령화, 생활습관 관련 위험, 환경적 요인, 진단기술의 발전으로 인한 발견율 증가 등의 요인에 기인합니다. 소라페닙 시장은 종양 성장과 혈관 신생에 관여하는 경로를 표적으로 하는 다중 키나아제 억제제를 제공함으로써 암 치료에 기여하고 있으며, 진행성 신세포암과 간세포암에 대한 효과적인 치료 옵션을 제공합니다. 예를 들어, 2023년 1월 미국 국립생물공학정보센터(NCBI)가 발표한 자료에 따르면, 2023년 미국에서는 약 195만 8,310건의 신규 암 발병과 60만 9,820건의 암 관련 사망이 발생할 것으로 예상했습니다. 그 결과, 암으로 인한 부담 증가가 소라페닙 시장의 성장을 가속하고 있습니다.

향후 몇 년 동안 의료비 지출 증가가 솔라페닙 시장의 성장을 견인할 것으로 예측됩니다. 보건의료 지출은 국민의 건강 유지 및 증진을 위한 의료 서비스, 치료, 의료기기, 공중 보건 정책에 할당되는 총 자금을 의미합니다. 의료비 지출 증가는 주로 만성질환의 유병률 증가에 기인하며, 이로 인해 장기 치료, 잦은 진료 상담, 고가의 지속적인 치료에 대한 수요가 증가하고 있습니다. 의료비 지출 증가는 첨단 암 치료에 대한 접근성 향상, 조기 진단 및 전문 의료 서비스 지원, 고비용 표적치료에 대한 환자의 경제적 부담 경감을 통해 소라페닙의 채택을 촉진할 것입니다. 예를 들어, 영국 통계청(ONS)에 따르면, 2024년 5월 기준 2022년부터 2023년까지 헬스케어 총 지출은 명목 기준으로 5.6% 증가했다고 합니다. 이는 2022년 0.9% 증가에 비해 큰 폭의 성장세를 보이고 있습니다. 따라서 의료비 지출 증가는 소라페닙 시장 확대에 기여하고 있다고 할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Sorafenib is a drug mainly used to treat certain types of cancer. It is categorized as a targeted therapy medication and functions by blocking specific enzymes and proteins that play a role in cancer cell proliferation and the development of blood vessels that supply tumors.

The primary product types of sorafenib include patented drugs and generic drugs. Patented drugs are medicines safeguarded by intellectual property rights, usually through a patent awarded to the company or individual responsible for discovering or developing the drug. These products are distributed through multiple channels, including hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. They are used for a range of applications, such as the treatment of kidney cancer, liver cancer, and thyroid cancer.

Tariffs have increased the cost of imported active pharmaceutical ingredients used in sorafenib manufacturing and formulation processes. These impacts are most evident in Asia Pacific manufacturing hubs that rely heavily on cross border api sourcing. Rising tariff related input costs have placed pressure on production margins and generic oncology drug pricing. This has influenced procurement strategies and capacity utilization decisions among manufacturers. However, tariffs are also encouraging domestic api production, local supplier development, and stronger pharmaceutical supply chain resilience over the long term.

The sorafenib market research report is one of a series of new reports from The Business Research Company that provides sorafenib market statistics, including sorafenib industry global market size, regional shares, competitors with a sorafenib market share, detailed sorafenib market segments, market trends and opportunities, and any further data you may need to thrive in the sorafenib industry. This sorafenib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sorafenib market size has grown steadily in recent years. It will grow from $1.29 billion in 2025 to $1.34 billion in 2026 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to clinical success of targeted kinase inhibitors, rising global cancer burden, approval of sorafenib for multiple indications, strong oncology r&d pipelines, patent-driven market expansion.

The sorafenib market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2030 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to growth in generic oncology drugs, increasing cancer diagnosis rates, focus on cost-effective cancer treatments, expansion of oncology care infrastructure, combination therapy research. Major trends in the forecast period include growing use of targeted cancer therapies, expansion of generic sorafenib products, rising adoption in liver and kidney cancer treatment, combination therapy approaches in oncology, improved access to oncology drugs in emerging markets.

The rising incidence of cancer is anticipated to drive the expansion of the sorafenib market in the coming years. Cancer is a collection of diseases marked by uncontrolled cell proliferation with the potential to invade nearby tissues and spread to other parts of the body. The growing prevalence of cancer is attributed to factors such as aging populations, lifestyle-related risks, environmental influences, and advancements in diagnostic technologies that have improved detection rates. The sorafenib market contributes to cancer treatment by offering a multi-kinase inhibitor that targets pathways involved in tumor growth and angiogenesis, providing an effective therapeutic option for advanced renal cell carcinoma and hepatocellular carcinoma. For example, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based biomedical information resource, reported that approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths occurred in the United States in 2023. Consequently, the increasing burden of cancer is fueling the growth of the sorafenib market.

The increase in healthcare spending is anticipated to drive the growth of the sorafenib market in the coming years. Healthcare expenditure refers to the overall funds allocated to healthcare services, medical treatments, equipment, and public health initiatives aimed at maintaining and improving population health. The growth in healthcare spending is largely attributed to the rising prevalence of chronic diseases, which leads to greater demand for long-term therapies, frequent clinical consultations, and expensive continuous care. Higher healthcare expenditure facilitates the adoption of sorafenib by improving access to advanced cancer treatments, supporting early diagnosis and specialist services, and enhancing patient affordability for high-cost targeted therapies. For example, in May 2024, according to the Office of National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms between 2022 and 2023, compared with an increase of 0.9% in 2022. Therefore, the growth in healthcare expenditure is contributing to the expansion of the sorafenib market.

In June 2024, Lotus Pharmaceuticals Co. Ltd., a Taiwan-based company involved in the manufacturing and sale of generic drugs, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed sum. This acquisition reinforces Lotus Pharmaceuticals' standing in the global generics market by incorporating Teva's wide-ranging pharmaceutical portfolio and operational expertise. It also broadens Lotus's market presence and product portfolio by integrating Teva's extensive oncology capabilities, including the production of sorafenib tablets. Teva Pharmaceutical Industries Ltd. is an Israel-based pharmaceutical company that produces sorafenib tablets.

Major companies operating in the sorafenib market are Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Natco Pharma, Hikma Pharmaceuticals PLC, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Accord Healthcare, Sandoz, MSN Laboratories, Alvogen

North America was the largest region in the sorafenib market in 2025. The regions covered in the sorafenib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sorafenib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sorafenib market consists of sales of nexavar, and sorafenib combination tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sorafenib Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses sorafenib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sorafenib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sorafenib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Patented Drugs; Generic Drugs
• 2) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• 3) By Application: Kidney Cancer; Liver Cancer; Thyroid Cancer
• Subsegments:
• 1) By Patented Drugs: Nexavar
• 2) By Generic Drugs: Generic Sorafenib Tosylate; Other Generic Variants
• Companies Mentioned: Bayer AG; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Natco Pharma; Hikma Pharmaceuticals PLC; Beacon Pharmaceuticals Ltd.; Hetero Healthcare Ltd.; Aprazer Healthcare Private Limited; Wellona Pharma; Anant Pharmaceuticals Pvt. Ltd.; Intelicure Lifescience; Zydus Lifesciences; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma; Accord Healthcare; Sandoz; MSN Laboratories; Alvogen
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Sorafenib Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Sorafenib Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Sorafenib Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Sorafenib Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Growing Use Of Targeted Cancer Therapies
  • 4.2.2 Expansion Of Generic Sorafenib Products
  • 4.2.3 Rising Adoption In Liver And Kidney Cancer Treatment
  • 4.2.4 Combination Therapy Approaches In Oncology
  • 4.2.5 Improved Access To Oncology Drugs In Emerging Markets

5. Sorafenib Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Specialty Pharmacies
• 5.5 Research Hospitals

6. Sorafenib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Sorafenib Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Sorafenib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Sorafenib Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Sorafenib Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Sorafenib Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Sorafenib Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Sorafenib Market Segmentation

• 9.1. Global Sorafenib Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Patented Drugs, Generic Drugs
• 9.2. Global Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
• 9.3. Global Sorafenib Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Kidney Cancer, Liver Cancer, Thyroid Cancer
• 9.4. Global Sorafenib Market, Sub-Segmentation Of Patented Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nexavar
• 9.5. Global Sorafenib Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Generic Sorafenib Tosylate, Other Generic Variants

10. Sorafenib Market Regional And Country Analysis

• 10.1. Global Sorafenib Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Sorafenib Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Sorafenib Market

• 11.1. Asia-Pacific Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Sorafenib Market

• 12.1. China Sorafenib Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Sorafenib Market

• 13.1. India Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Sorafenib Market

• 14.1. Japan Sorafenib Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Sorafenib Market

• 15.1. Australia Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Sorafenib Market

• 16.1. Indonesia Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Sorafenib Market

• 17.1. South Korea Sorafenib Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Sorafenib Market

• 18.1. Taiwan Sorafenib Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Sorafenib Market

• 19.1. South East Asia Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Sorafenib Market

• 20.1. Western Europe Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Sorafenib Market

• 21.1. UK Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Sorafenib Market

• 22.1. Germany Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Sorafenib Market

• 23.1. France Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Sorafenib Market

• 24.1. Italy Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Sorafenib Market

• 25.1. Spain Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Sorafenib Market

• 26.1. Eastern Europe Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Sorafenib Market

• 27.1. Russia Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Sorafenib Market

• 28.1. North America Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Sorafenib Market

• 29.1. USA Sorafenib Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Sorafenib Market

• 30.1. Canada Sorafenib Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Sorafenib Market

• 31.1. South America Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Sorafenib Market

• 32.1. Brazil Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Sorafenib Market

• 33.1. Middle East Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Sorafenib Market

• 34.1. Africa Sorafenib Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Sorafenib Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Sorafenib Market Regulatory and Investment Landscape

36. Sorafenib Market Competitive Landscape And Company Profiles

• 36.1. Sorafenib Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Sorafenib Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Sorafenib Market Company Profiles
  • 36.3.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Sorafenib Market Other Major And Innovative Companies

• Natco Pharma, Hikma Pharmaceuticals PLC, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Accord Healthcare, Sandoz, MSN Laboratories, Alvogen

38. Global Sorafenib Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Sorafenib Market

40. Sorafenib Market High Potential Countries, Segments and Strategies

• 40.1 Sorafenib Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Sorafenib Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Sorafenib Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer